Screening for future cardiovascular disease using age alone compared with multiple risk factors and age

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Wald, Nicholas J ^a   Simmonds, Mark ^a   Morris, Joan K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE FREE SURVIVAL; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; INTERMETHOD COMPARISON; MALE; PROPHYLAXIS; QUALITY OF LIFE; RISK FACTOR; SCREENING; SEX RATIO; VALIDATION PROCESS; ADOLESCENT; CHILD; ECONOMICS; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 79955778070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018742     Document Type: Article

References (27)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-57.
2. Wald NJ, Law MR, (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419-25.
3. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, et al. (2009) Effects of the polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373: 1341-51.
4. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society (2005) JBS 2: Joint British Societies' Guidelines on Prevention of Cardiovascular Disease in Clinical Practice. Heart 91 (supplement 5): v1-v52.
5. Office for National Statistics (2007) 2005 Mortality Statistics, Series DH2 Number 32. HMSO, London, UK.
6. Office for National Statistics (2003) Health Survey for England, 2003. The Stationery Office, UK.
7. Anderson K, Odell P, Wilson P, Kannel W, (1991) Cardiovascular disease risk profiles. American Heart Journal 121: 293-8.
8. Law MR, Wald NJ, Rudnicka AR, (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423-6.
9. Law MR, Wald NJ, Morris JK, Jordan RE, (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427-32.
10. Law MR, Morris JK, Wald NJ, (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665.
11. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829-39.
12. Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-13.
13. Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 366: 1267-78.
14. Law MR, Morris JK, Wald NJ, (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665.
15. Law M, Wald NJ, Morris JK, (2003) Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technology Assessment 7: 1-106.
16. National Institute for Clinical Excellence (2008) Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guidance 67.
17. Brindle P, Emberston J, Lample F, Walker M, Whincup P, et al. (2003) Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327: 1267-70.
18. Brindle P, Beswick A, Fahey T, Ebrahim S, (2006) The accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92: 1752-1759.
19. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117: 743-753.
20. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR, (2008) C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds risk score for men. Circulation 118: 2243-2251.
21. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, et al. (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336: a332.
22. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, et al. (1988) Maternal serum screening for Down's syndrome in early pregnancy. BM J 297: 883-887.
23. Wald NJ, Law M, Watt H, Wu T, Bailey A, et al. (1994) Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 343: 75-79.
24. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, et al. (2005) Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ 331: 551-4.
25. Wald NJ, Hackshaw AK, Frost CD, (1999) When can a risk factor be used as a worthwhile screening test? BMJ 319: 1562-65.
26. Wald NJ, Morris JK, Rish S, (2005) The efficacy of combining several risk factors as a screening test. J Med Screen 12: 197-201.
27. European Medicines Agency (2008) Guideline on the evaluation of medicinal products for cardiovascular disease prevention. Doc ref EMEA/CHMP/EWP/311890/2007. European Medicines Agency, London.